Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
TmCD19-IL18 by Kite Pharma for Marginal Zone B-cell Lymphoma: Likelihood of Approval
TmCD19-IL18 is under clinical development by Kite Pharma and currently in Phase I for Marginal Zone B-cell Lymphoma. According to...
TmCD19-IL18 by Kite Pharma for Primary Mediastinal B-Cell Lymphoma: Likelihood of Approval
TmCD19-IL18 is under clinical development by Kite Pharma and currently in Phase I for Primary Mediastinal B-Cell Lymphoma. According to...
TmCD19-IL18 by Kite Pharma for Anaplastic Large Cell Lymphoma (ALCL): Likelihood of Approval
TmCD19-IL18 is under clinical development by Kite Pharma and currently in Phase I for Anaplastic Large Cell Lymphoma (ALCL). According...
TmCD19-IL18 by Kite Pharma for Follicular Lymphoma: Likelihood of Approval
TmCD19-IL18 is under clinical development by Kite Pharma and currently in Phase I for Follicular Lymphoma. According to GlobalData, Phase...
TmCD19-IL18 by Kite Pharma for Mantle Cell Lymphoma: Likelihood of Approval
TmCD19-IL18 is under clinical development by Kite Pharma and currently in Phase I for Mantle Cell Lymphoma. According to GlobalData,...
TmCD19-IL18 by Kite Pharma for Diffuse Large B-Cell Lymphoma: Likelihood of Approval
TmCD19-IL18 is under clinical development by Kite Pharma and currently in Phase I for Diffuse Large B-Cell Lymphoma. According to...
TmCD19-IL18 by Kite Pharma for Chronic Lymphocytic Leukemia (CLL): Likelihood of Approval
TmCD19-IL18 is under clinical development by Kite Pharma and currently in Phase I for Chronic Lymphocytic Leukemia (CLL). According to...
TmCD19-IL18 by Kite Pharma for Non-Hodgkin Lymphoma: Likelihood of Approval
TmCD19-IL18 is under clinical development by Kite Pharma and currently in Phase I for Non-Hodgkin Lymphoma. According to GlobalData, Phase...